childhood immunoblastic large cell lymphoma
Showing 1 - 25 of >10,000
Pediatric Cancer, Hodgkin Disease, CD30-Positive DLBCL Trial in Milwaukee (anti-CD30 Bispecific Antibody-armed
Not yet recruiting
- Pediatric Cancer
- +11 more
- anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells (CD30 biAb-AATC)
-
Milwaukee, WisconsinChildren's Wisconsin
Sep 14, 2022
T-cell Lymphoma, NK-Cell Lymphoma, T-cell Prolymphocytic Leukemia Trial in United States (Optional Blood Sample, Optional Nail
Recruiting
- T-cell Lymphoma
- +30 more
- Optional Blood Sample
- Optional Nail Sample
-
Duarte, California
- +25 more
Jul 28, 2023
Hematopoietic/Lymphoid Cancer, Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Completed
- Hematopoietic/Lymphoid Cancer
- +135 more
- beclomethasone dipropionate
- +4 more
-
Hackensack, New Jersey
- +1 more
Feb 1, 2021
Diffuse Large Cell Lymphoma, Non-Hodgkin Lymphoma, Burkitt Lymphoma Trial run by the National Cancer Institute (NCI)
Recruiting
- Diffuse Large Cell Lymphoma
- +4 more
- Vincristine
- +6 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Feb 2, 2023
High-Dose Methotrexate Clearance in Diffuse Large B-Cell
Recruiting
- Central Nervous System Lymphoma
- Diffuse Large B-Cell Lymphoma
- Non-Interventional Study
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Sep 8, 2023
Diffuse Large B-cell Lymphoma Recurrent, Diffuse Large B Cell Lymphoma Refractory Trial in Hangzhou (Anlotinib HCl, Rituximab,
Recruiting
- Diffuse Large B-cell Lymphoma Recurrent
- Diffuse Large B Cell Lymphoma Refractory
- Anlotinib hydrochloride, Rituximab, gemcitabine, oxaliplatin
-
Hangzhou, Zhejiang, ChinaZhejiang Cancer Hospital
Oct 12, 2023
Recurrent DLBCL, Refractory Diffuse Large B-cell Lymphoma Trial in Tianjin (RC19D2 cell injection)
Recruiting
- Recurrent Diffuse Large B-Cell Lymphoma
- Refractory Diffuse Large B-cell Lymphoma
- RC19D2 cell injection
-
Tianjin, Tianjin, ChinaHematology Hospital of the Chinese Academy of Medical Sciences
Sep 14, 2023
Diffuse Large B Cell Lymphoma | DLBCL Recurrent/Refractory Trial (ZR2-ICE)
Not yet recruiting
- Diffuse Large B Cell Lymphoma | Diffuse Large B-Cell Lymphoma Recurrent/Refractory
- (no location specified)
Sep 5, 2023
Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Mature T- and NK-Cell
Active, not recruiting
- Recurrent Anaplastic Large Cell Lymphoma
- +10 more
- Pembrolizumab
- Romidepsin
-
Houston, TexasM D Anderson Cancer Center
Jan 30, 2023
Relapsed or Refractory Diffuse Large B-cell Lymphoma Trial in Beijing (BEBT-908 for injection)
Active, not recruiting
- Relapsed or Refractory Diffuse Large B-cell Lymphoma
- BEBT-908 for injection
-
Beijing, ChinaCancer Hospital Chinese Academy of Medical Sciences
Oct 8, 2023
Adult Grade III Lymphomatoid Granulomatosis, Cutaneous B-cell Non-Hodgkin Lymphoma, MALT Trial in Duarte (biological, procedure,
Active, not recruiting
- Adult Grade III Lymphomatoid Granulomatosis
- +23 more
- autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells
- +2 more
-
Duarte, CaliforniaCity of Hope Medical Center
Jan 4, 2023
DLBCL Trial (Polatuzumab Vedotin)
Not yet recruiting
- Diffuse Large B-Cell Lymphoma
- Polatuzumab Vedotin
- (no location specified)
Jul 12, 2023
Communication Training Intervention for Large B-Cell Lymphoma
Recruiting
- Lymphoma, B-Cell
- +5 more
- Hematolo-GIST Training
- Participants Appointment
-
New York, New York
- +2 more
Jul 3, 2023
Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma Trial in Tianjin (CD19-targeted Chimeric Antigen Receptor(CAR) T Cells)
Recruiting
- Lymphoma, Non-Hodgkin
- Diffuse Large B Cell Lymphoma
- CD19-targeted Chimeric Antigen Receptor(CAR) T Cells
-
Tianjin, Tianjin, ChinaTianjin Cancer Hospital
Nov 19, 2023
AIDS-related Diffuse Large Cell Lymphoma, AIDS-related Diffuse Mixed Cell Lymphoma, AIDS-related Diffuse Small Cleaved Cell
Completed
- AIDS-related Diffuse Large Cell Lymphoma
- +8 more
- cyclophosphamide
- +7 more
-
Eldoret, Kenya
- +1 more
Sep 12, 2022
DLBCL - Diffuse Large B Cell Lymphoma, Follicular Lymphoma Trial in Xiamen (Lenalidomide combined with G-CHOP (LO CHOP))
Recruiting
- DLBCL - Diffuse Large B Cell Lymphoma
- Follicular Lymphoma
- Lenalidomide combined with G-CHOP (LO CHOP)
-
Xiamen, Fujian, ChinaBing Xu
Nov 28, 2023
Diffuse Large B Cell Lymphoma Trial in Shanghai (Zanubrutinib, Polatuzumab vedotin and Rituximab)
Recruiting
- Diffuse Large B Cell Lymphoma
- Zanubrutinib, Polatuzumab vedotin and Rituximab
-
Shanghai, Shanghai, ChinaZhongshan Hospital,Fudan University
Jul 10, 2023
DLBCL Trial in Jinan (Mitoxantrone Hydrochloride Liposome Injection)
Not yet recruiting
- Diffuse Large B-Cell Lymphoma
- Mitoxantrone Hydrochloride Liposome Injection
-
Jinan, Shandong, ChinaAffiliated Cancer Hospital of Shandong First Medical University
May 16, 2023
Diffuse Large B Cell Lymphoma Trial in Shanghai (Zanubrutinib, Polatuzumab Vedotin, Rituximab)
Recruiting
- Diffuse Large B Cell Lymphoma
- Zanubrutinib, Polatuzumab Vedotin, Rituximab
-
Shanghai, Shanghai, ChinaZhongshan Hospital,Fudan University
Jul 10, 2023
Diffuse Large B-cell Lymphoma Trial (Rituximab, Mitoxantrone HCl liposome, Cyclophosphamide)
Not yet recruiting
- Diffuse Large B-cell Lymphoma
- Rituximab
- +4 more
- (no location specified)
Mar 9, 2023
DLBCL Trial (Acalabrutinib, Rituximab)
Not yet recruiting
- Diffuse Large B-Cell Lymphoma
- Acalabrutinib
- Rituximab
- (no location specified)
Jul 11, 2023
Relmacabtagene Autoleucel in Patients With LBCL
Recruiting
- Large B-cell Lymphoma
- Relmacabtagene Autoleucel
-
Shanghai, Shanghai, ChinaRuijin Hospital Affiliated to Shanghai Jiao Tong University Scho
Nov 15, 2023
Follicular Lymphoma, B-Cell Lymphoma, Mantle Cell Lymphoma Trial in New York (Tazemetostat Pill)
Not yet recruiting
- Follicular Lymphoma
- +3 more
- Tazemetostat Pill
-
New York, New YorkWeill Cornell Medicine/NewYork-Presbyterian Hospital
Jun 28, 2023